Article citationsMore>>

Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M.R., Follana, P., Bollag, D. and Ray-Coquard, I. (2014) Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. Journal of Clinical Oncology, 32, 1302-1308.
https://doi.org/10.1200/JCO.2013.51.4489

has been cited by the following article:

• TITLE: Difficult Conversations and Painful Decisions: When Should Patients with Progressive Cancer Stop Chemotherapy?

  AUTHORS: Jeanine Staples, Varvara Mazina, Bethany-Rose Daubman, Annekathryn Goodman

  KEYWORDS: Chemotherapy, Chemotherapy Resistance, Chemotherapy Cessation, Palliative Chemotherapy, Recurrent Cancer and Prognosis, Best Supportive Care, Medical Futility, End-of-Life

  JOURNAL NAME: Journal of Cancer Therapy, Vol.13 No.1, January 24, 2022

  ABSTRACT: Introduction: The decision to stop anti-cancer treatment is fraught with many challenges for the oncologist, the patient, and their caregivers. This review examines the special considerations surrounding the decision to cease chemotherapy in terminally ill cancer patient. Methods: A comprehensive literature search was conducted to find relevant publications on chemotherapy cessation. A total of 2700 records were retrieved and 141 were identified as eligible for inclusion in this review. Results: Palliative chemotherapy does not achieve the goal of tumor-related symptom reduction for patients who have experienced progressive disease with more than two prior lines of chemotherapy. ECOG performance status is a crucial predictor of response to therapy and chemotherapy-related complications. Challenges to stopping chemotherapy at the end of life are multifactorial and are both patient and physician-driven. Racial, ethnic, and income-based disparities are seen in the timing and quality of end-of-life conversations offered by physicians to their patients. Conclusions: The decision to cease chemotherapy is one that should be approached with careful consideration and accurate information. Clear communication, compassion and empathy are important components to the therapeutic relationship. Early involvement of palliative care and clear conversations about prognosis and the expected utility of further chemotherapy is essential to conduct the best possible care for cancer patients at the end of life.